Takeda Pharmaceutical Company(TAK)
$21.43+0.31 (+1.47%)
TAK
Takeda Pharmaceutical Company financials statements
$21.43
At close:+0.31 (+1.47%)
Want to see TAK full AI Analyst Report?
Takeda Pharmaceutical Company (TAK) Income Statement
1,372 Followers
Takeda Pharmaceutical Company Income Statement
Last quarter (Q2 2026), Takeda Pharmaceutical Company's total revenue was ¥1.19T, an increase of 6.68% from the same quarter last year. In Q2, Takeda Pharmaceutical Company's net income was ¥192.43B. See Takeda Pharmaceutical Company’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| ¥ 4.78T | ¥ 4.58T | ¥ 4.26T | ¥ 4.03T | ¥ 3.57T | |
| ¥ 2.44T | ¥ 3.00T | ¥ 2.83T | ¥ 2.78T | ¥ 2.46T | |
| ¥ 1.87T | ¥ 2.66T | ¥ 2.62T | ¥ 2.29T | ¥ 2.00T | |
| Depreciation and Amortization | ¥ 721.13B | ¥ 761.40B | ¥ 728.00B | ¥ 664.40B | ¥ 583.15B |
| ¥ 1.38T | ¥ 1.21T | ¥ 1.23T | ¥ 1.28T | ¥ 1.18T | |
| ¥ 573.04B | ¥ 342.59B | ¥ 214.07B | ¥ 490.50B | ¥ 460.84B | |
| ¥ -297.16B | ¥ -167.50B | ¥ -161.28B | ¥ -115.42B | ¥ -158.27B | |
| ¥ 275.88B | ¥ 175.08B | ¥ 52.79B | ¥ 375.09B | ¥ 302.57B | |
| ¥ 203.33B | ¥ 107.93B | ¥ 144.07B | ¥ 317.02B | ¥ 230.06B | |
| Per Share Metrics | |||||
| Basic EPS | ¥ 63.91 | ¥ 34.17 | ¥ 46.05 | ¥ 102.15 | ¥ 73.57 |
| Diluted EPS | ¥ 63.91 | ¥ 33.62 | ¥ 45.58 | ¥ 100.97 | ¥ 72.94 |
| Weighted Average Shares Outstanding | 3.15B | 3.21B | 3.13B | 3.10B | 3.13B |
| Weighted Average Shares Outstanding (Diluted) | 3.21B | 3.21B | 3.16B | 3.14B | 3.15B |
Currency in JPY

